Imatinib and solid tumours;Imatinib et tumeurs solides

Bulletin du Cancer

Volumn 95, Issue 1, 2008, Pages 99-106

  Arifi, Samia ^a   El Sayadi, Hiba ^b   Dufresne, Armelle ^a   Ray Coquard, Isabelle ^c   Fayette, Jérôme ^b,c   Méeus, Pierre ^c   Ranchère, Dominique ^c   Decouvelaere, Anne Valérie ^c   Alberti, Laurent ^b   Tabone Eglinger, Séverine ^b   Blay, Jean Yves ^a,b,c   Cassier, Philippe ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSERM   (France)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

GIST; Imatinib; KIT; PDGFR; Solid tumour; Tyrosine kinase

Indexed keywords

IMATINIB; STEM CELL FACTOR; ABELSON KINASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DRUG STRUCTURE; EUROPE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MELANOMA; OVARY CANCER; PROSTATE CANCER; REVIEW; UNITED STATES; CHEMICALLY INDUCED DISORDER; DERMATOFIBROSARCOMA PROTUBERANS; DRUG ANTAGONISM; FEMALE; MALE; METABOLISM; NEOPLASM; SECOND CANCER; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; DERMATOFIBROSARCOMA; FEMALE; FUSION PROTEINS, BCR-ABL; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SKIN NEOPLASMS;

EID: 39149132183     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0557     Document Type: Review

References (77)

1. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005 ; 105 : 2640-53.
2. Savage DG, Antman KH. Imatinib mesylate : a new oral targeted therapy. N Engl J Med 2002 ; 346 : 683-93.
3. Mauro MJ, Druker BJ. STI571 : targeting BCR-ABL as therapy for CML. Oncologist 2001 ; 6 : 233-8.
4. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004 ; 22 : 3813-25.
5. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004 ; 22 : 4514-22.
6. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002 ; 1 : 493-502.
7. Reinmuth N, Stoeltzing O, Liu W, Ahmad SA, Jung YD, Fan F, et al. Endothelial survival factors as targets for antineoplastic therapy. Cancer J 2001 ; 7(Suppl 3) : S109-S119.
8. Monges G, Coindre J, Scoazec J, Bouvier A, Blay J, Loria-Kanza Y, et al. Incidence of gastrointestinal stromal tumors (GISTs) in France : results of the Progist survey conducted among pathologists. Asco Meeting Abstracts 2007 ; 25 : 10047.
9. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors : the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era : a population-based study in western Sweden. Cancer 2005 ; 103 : 821-9.
10. Ray-Coquard I, Le Cesne A, Michallet V, Boukovinas I, Ranchere D, Thiesse P, et al. Tumeurs stromales du tractus digestif : actualités 2003. Bull Cancer 2003 ; 90 : 69-76.
11. Ray-Coquard I, Saba C, Ducimetière F, Confavreux C, Rustam F, Brantus JF, et al. A. Traitement multidisciplinaire des tumeurs stromales gastrointestinales : cas cliniques en situation adjuvante, néoadjuvante, avancée, en échappement. Bull Cancer 2006 ; 93 : S181-S189.
12. Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L, et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986 ; 320 : 415-21.
13. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998 ; 279 : 577-80.
14. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001 ; 61 : 8118-21.
15. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003 ; 299 : 708-10.
16. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors : proof of concept and therapeutic implications. Am J Surg Pathol 2004 ; 28 : 889-94.
17. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000 ; 295 : 139-45.
18. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein : biological and clinical implications. Oncogene 2001 ; 20 : 5054-8.
19. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastroinrestinal stromal tumor. N Engl J Med 2001 ; 344 : 1052-6.
20. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato DI, Paola E, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours : a phase I study. Lancet 2001 ; 358 : 1421-3.
21. Demetri GD, von, Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts P, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002 ; 347 : 472-80.
22. Verweij J, van, Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003 ; 39 : 2006-11.
23. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib : randomised trial. Lancet 2004 ; 364 : 1127-34.
24. Rankin C, Von Mehren M, Blanke C, Benjamin R, Fletcher CDM, Bramwell V, et al. Dose effect of imatinib in patients with metastatic GIST. Phase III Sarcoma Group Study S0033. Asco meeting abstracts 2004 ; 22 : 9005.
25. Blay JY, Bonvalot S, Casali P, Choi H, Biec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of Esmo. Ann Oncol 2005 ; 16 : 566-78.
26. DeMatteo RP, Owzar K, Maki RG, Pisters P, Blackstein M, Antonescu CR, et al. Adjuvant imatinib mesylate increases recurrence free survival in patients with completely resected localized primary gastrointestinal stromal tumor : North American Intergroup Phase III trial Acosog Z9001. Asco Meeting Abstracts 2007 ; 25 : 10079.
27. Rios M, LeCesne A, Bui B, Adenis A, Bertucci F, Duffaud F, et al., and French Sarcoma Group. Interruption of imatinib in GIST patients with advanced disease after one year of treatment : updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival. Asco meeting abstracts 2007 ; 25 : 10016.
28. Le Cesne A, Ray-Coquard I, Bui B, Rios M, Adenis A, Bertucci F, et al. Continuous versus interruption of imatinib in responding patients with advanced GIST after three years of treatment : A prospective randomized phase III trial of the French Sarcoma Group. Asco Meeting Abstracts 2007 ; 25 : 10005.
29. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006 ; 42 : 1093-103.
30. Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J, and GIST Meta-analysis Group. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors : a meta-analyis based on 1,640 patients. Asco meeting abstracts 2007 ; 25 : 10004.
31. Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006 ; 24 : 1195-203.
32. McArthur GA. Molecular targeting of dermatofibrosarcoma protuberans : a new approach to a surgical disease. J Natl Compr Canc Netw 2007 ; 5 : 557-62.
33. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001 ; 61 : 5778-83.
34. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Biec-Rychter M, Corless C, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib : Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005 ; 23 : 866-73.
35. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002 ; 20 : 3586-91.
36. Maki RG, Awan RA, Dixon RH, Jhanwar S, Anronescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002 ; 20(100) : 623-6.
37. Baars A, Pinedo HM. {Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans}. Ned Tijdschr Geneeskd 2003 ; 147 : 2072-6.
38. Mizutani K, Tamada Y, Hara K, Tsuzuki T, Saeki H, Tamaki K, et al. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004 ; 151 : 235-7.
39. Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005 ; 16 : 461-6.
40. Kasper B, Lossignol D, Gil T, Flamen P, De Saint-Aubain N, Awada A. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anticancer Drugs 2006 ; 17 : 1223-5.
41. Mehrany K, Swanson NA, Heinrich MC, Weenig RH, Lee KK, White CR, et al. Dermatofibrosarcoma protuberans : a partial response to imatinib therapy. Dermatol Surg 2006 ; 32 : 456-9.
42. Nikolaou M, Valavanis C, Aravantinos G, Fountzilas G, Tamvakis N, Lekka I, et al. Kit expression in male germ cell tumors. Anticancer Res 2007 ; 27 : 1685-8.
43. Sakuma Y, Sakurai S, Oguni S, Hironaka M, Saito K. Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci 2003 ; 94 : 486-91.
44. Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004 ; 164 : 305-13.
45. Nakai Y, Nonomura N, Oka D, Shiba M, Arai Y, Nakayama M, et al. KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors. Biochem Biophys Res Commun 2005 ; 337 : 289-96.
46. Biermann K, Goke F, Nettersheim D, Eckert D, Zhou H, Kahl P, et al. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma. J Pathol 2007 ; 213 : 311-8.
47. Willmore-Payne C, Holden JA, Chadwick BE, Layfield LJ. Detection of c-kit exons 11- and 17-activating mutations in testicular seminomas by high-resolution melting amplicon analysis. Mod Pathol 2006 ; 19 : 1164-9.
48. Izquierdo MA, Van der Valk V, Van Ark-Otte J, Rubio G, Germa-Lluch JR, Ueda R, et al. Differential expression of che c-kit proto-oncogene in germ cell tumours. J Pathol 1995 ; 177 : 253-8.
49. Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, et al. Imatinib mesylate inhibits Leydig cell tumor growth : evidence for in vitro and in vivo activity. Cancer Res 2005 ; 65 : 1897-903.
50. Froehner M, Beuthien-Baumann B, Dittert DD, Schuler U, Wirth MP. Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor. Cancer Chemother Pharmacol 2006 ; 58 : 716-8.
51. Einhorn LH, Brames MJ, Heinrich MC, Corless CL, Madani A. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 2006 ; 29 : 12-3.
52. Eton O, Billings L, Kim K, Prieto V, Davis D, Frazier ML, et al. Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma. Asco meeting abstracts 2004 ; 22 : 7528.
53. Ugurel S, Hildenbrand R, Zimpfer A, La, Rosee P, Paschka P, Sucker A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005 ; 92 : 1398-405.
54. Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma : significant toxicity with no clinical efficacy. Cancer 2006 ; 106 : 2005-11.
55. Fayette J, Dufresne A, Penel N, Le Cesne A, Bui Nguyen B, Tubiana-Hulin M, et al. Imatinib for the treatment of aggressive fibromatosis/desmoid tumors failing local treatment : updated outcome and predictive factors for progression free survival. A FNCLCC French Sarcoma Group-GETO study. Asco meeting abstracts 2007 ; 25 : 10062.
56. Shen SS, Zhang PS, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 2003 ; 30 : 539-47.
57. Leithner A, Gapp M, Radl R, Pascher A, Krippl P, Leithner K, et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol 2005 ; 58 : 1152-6.
58. Goncalves A, Monges G, Yang Y, Palmerini F, Dubreuil P, Noguchi T, et al. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J Natl Cancer Inst 2006 ; 98 : 562-3.
59. Seinfeld J, Kleinschmidt-Demasters BK, Tayal S, Lillehei KO. Desmoid-type fibromatoses involving the brachial plexus : treatment options and assessment of c-KIT mutational status. J Neurosurg 2006 ; 104 : 749-56.
60. Liegl B, Leithner A, Bauernhofer T, Windhager R, Guelly C, Regauer S, et al. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours : is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours? Histopathology 2006 ; 49 : 576-81.
61. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996 ; 56 : 370-6.
62. Soria JC, Johnson BE, Chevalier TL. Imatinib in small cell lung cancer. Lung Cancer 2003 ; 41(Suppl 1) : S49-S53 ; (S49-53).
63. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003 ; 9 : 5880-7.
64. Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein : a phase II clinical trial. Cancer 2005 ; 103 : 2128-31.
65. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM, Morton RF, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer : a CALGB and NCCTG study. Ann Oncol 2005 ; 16 : 1811-6.
66. Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon J, et al. A. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 2007 ; 83 : 53-60.
67. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005 ; 20(23) : 9359-68.
68. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme : a patient series. Ann Oncol 2005 ; 16 : 1702-8.
69. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003 ; 98 : 758-64.
70. Lassus H, Sihto H, Leminen A, Nordling S, Joensuu H, Nupponen NN, et al. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer 2004 ; 91 : 2048-55.
71. Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 2004 ; 10 : 681-90.
72. Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 2004 ; 10 : 897-908.
73. Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006 ; 101 : 126-31.
74. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006 ; 13 : 535-40.
75. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007 ; 13 : 234-40.
76. Roy L, Guilhot J, Martineau G, Larchee R, Guilhot F. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005 ; 19 : 1689-92.
77. Pilot PR, Sablinska K, Owen S, Hatfield A. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006 ; 20 : 148.